Eupraxia Pharmaceuticals Inc
Open
$10.09
Prev. Close
$10.07
High
$10.09
Low
$10.03
Market Snapshot
$197.53M
-0.93
49
Eupraxia Pharmaceuticals, Inc. operates as a drug delivery technology company in Canada. The company is headquartered in Victoria, British Columbia and currently employs 33 full-time employees. The company went IPO on 2021-03-09. The firm is focused on the development of locally delivered, extended-release products. The Company’s lead product candidate, EP-104, is designed to address the significant unmet medical need and market demand for conditions where long-lasting symptom relief is essential to effective treatment. The primary targets for EP-104 have been identified as knee osteoarthritis (OA) and eosinophilic esophagitis (EoE). The product in development for OA is called EP-104IAR and the product in development in EoE is called EP-104GI. DiffuSphere, a proprietary, polymer based micro-sphere technology, is designed to facilitate targeted drug delivery, with extended duration of effect, and offers multiple, highly tunable pharmacokinetic (PK) profiles.
emptyResult
Eupraxia Pharmaceuticals, Inc. operates as a drug delivery technology company in Canada. The company is headquartered in Victoria, British Columbia and currently employs 33 full-time employees. The company went IPO on 2021-03-09. The firm is focused on the development of locally delivered, extended-release products. The Company’s lead product candidate, EP-104, is designed to address the significant unmet medical need and market demand for conditions where long-lasting symptom relief is essential to effective treatment. The primary targets for EP-104 have been identified as knee osteoarthritis (OA) and eosinophilic esophagitis (EoE). The product in development for OA is called EP-104IAR and the product in development in EoE is called EP-104GI. DiffuSphere, a proprietary, polymer based micro-sphere technology, is designed to facilitate targeted drug delivery, with extended duration of effect, and offers multiple, highly tunable pharmacokinetic (PK) profiles.
Recently from Cashu
Eupraxia Pharmaceuticals Reports Positive Phase 1b/2a Results for EoE Treatment EP-104GI
Eupraxia Pharmaceuticals Unveils Promising Phase 1b/2a Trial Results for EP-104GI in Eosinophilic Esophagitis Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology firm located in Victoria, Br…
Eupraxia Pharmaceuticals' EP-104GI Shows Promise for Eosinophilic Esophagitis in Trial Results
Eupraxia Pharmaceuticals Advances Treatment for Eosinophilic Esophagitis with Promising Trial Results Eupraxia Pharmaceuticals Inc. announces encouraging results from its ongoing RESOLVE Phase 1b/2a t…
Eupraxia Pharmaceuticals Inc. Achieves Promising Results in Eosinophilic Esophagitis Treatment Trial
Innovative Treatment for Eosinophilic Esophagitis: Eupraxia Pharmaceuticals' Promising Trial Results Eupraxia Pharmaceuticals Inc. is making significant strides in the field of eosinophilic esophagiti…